Physicians & Researchers

Since it was founded in 2012, the CDCN has harnessed the power of its global network of physicians and researchers to relentlessly pursue a cure for Castleman disease. The CDCN has funded or supported over 40 high-impact studies that have led to breakthroughs including the first-ever diagnostic criteria, the first-ever treatment guidelines, the discovery of a novel treatment target for iMCD (mTOR pathway) and sirolimus as a new treatment, and more. Physicians & researchers can join the CDCN’s physician & researcher community to gain access to all resources in this section.

Learn about the latest in CD Research:

 

    • Lists and explains all current CDCN research projects with a description of each project and a corresponding status.

Clinical Trials

    • A clinical trial is open in the USA to investigate sirolimus for iMCD patients who did not respond to anti-IL-6 therapy (siltuximab) at the University of Pennsylvania and the University of Arkansas for Medical Sciences

Resources

    • Access continuously updated resources including full-print versions of recent CD publications, the CD UpToDate pages, and our pathology toolkit.

iMCD Treatment Targets

Collaborate With Us

CSTL @ UPenn

    • The Center for Study & Treatment of Castleman & Inflammatory Lymphadenopathies (CSTL) was started by CDCN Co-Founder Dr. Fagjenbaum at the Perelman School of Medicine at the University of Pennsylvania.
Arrow Shape Facebook Instagram Twitter Youtube Play Arrow Left